Objective To realize the relationship between substance P(SP) and abnormal gastrointestinal tran- sit. Methods By radioimmunoassay, concentration of SP in sigmoid mucosa was determined in 12 healthy volun- teers, 15 slow and 10 fast transit patients. ResultsThe concentration was (27.68±15.42)μg/g, (24.07+5.76)μg/g and (28.61± 18.34)μg/g,respectively. They had no statistical difference. Conclusion There was no relationship be- tween concentration of SP in sigmoid mucosa and abnormal gastrointestinal transit.

Objective To investigate the efficacy and safety of interventional sclerotherapy for cystic lymphatic malformation(cLM).Methods A total of 92 cases of cLM were enrolled in this study.Forty-seven cases were macrocystic lymphatic malformation(LM),32 cases were mixed LM,and 13 cases were microcystic LM.At the first treatment,56 cases with clear or light yellow cystic fluid were defined as non-bleeding group;Thirty-six cases with cloudy or dark red cystic fluid were defined as bleeding group.Sclero-therapy was performed under the guidance of fluoroscopy or ultrasonic(US),followed by an outpatient or a telephone follow-up at least 3 months after operation.Results Ninety-two patients received 140 times of interventional sclerotherapy,with an average of 1.53 times.The overall cure rate was 56.5%and the overall effective rate was 95.7%.The results of subgroup analysis showed that the overall effective rate of macrocystic and mixed LM was higher than that of microcystic LM,while the overall effective rate of macrocystic and mixed LM had no statistical difference.The cure rate of macrocystic LM was higher than that of mixed and microcystic LM,but there was no significant difference between mixed and microcystic LM.Besides,there were no statistical differences in the overall effective rate and the cure rate between the bleeding group and the non-bleeding group.Conclusion Interventional sclerotherapy is a safe and effective treatment for cLM patients.The efficacy of interventional sclerotherapy is not affected by the presence or absence of intracapsular hemorrhage during the first treatment.

COVID-19 is caused by coronavirus SARS-CoV-2. Current systemic vaccines generally provide limited protection against viral replication and shedding within the airway. Recombinant VSV (rVSV) is an effective vector which inducing potent and comprehensive immunities. Currently, there are two clinical trials investigating COVID-19 vaccines based on VSV vectors. These vaccines were developed with spike protein of WA1 which administrated intramuscularly. Although intranasal route is ideal for activating mucosal immunity with VSV vector, safety is of concern. Thus, a highly attenuated rVSV with three amino acids mutations in matrix protein (VSV_MT) was developed to construct safe mucosal vaccines against multiple SARS-CoV-2 variants of concern. It demonstrated that spike protein mutant lacking 21 amino acids in its cytoplasmic domain could rescue rVSV efficiently. VSV_MT indicated improved safeness compared with wild-type VSV as the vector encoding SARS-CoV-2 spike protein. With a single-dosed intranasal inoculation of rVSV_ΔGMT-S_Δ21, potent SARS-CoV-2 specific neutralization antibodies could be stimulated in animals, particularly in term of mucosal and cellular immunity. Strikingly, the chimeric VSV encoding S_Δ21 of Delta-variant can induce more potent immune responses compared with those encoding S_Δ21 of Omicron- or WA1-strain. VSV_MT is a promising platform to develop a mucosal vaccine for countering COVID-19.